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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER2029Genomics in Cardiovascular DiseaseRobert Roberts, A. J. Marian, Sonny Dandona, Alexandre F. R. Stewart
In this State-of-the-Art paper, Roberts and colleagues provide a brief history and background
of human genomics and cover the major milestones and progress of genetic sequencing.
The genetic basis of cardiac disease caused by single-gene disorders, such as hypertrophic
cardiomyopathy, and more complex polygenic disorders, such as coronary artery disease, are
discussed and reviewed. Challenges faced in this field, namely information storage, retrieval,
and integration of the data generated, are also presented.CLINICAL RESEARCH LATE-BREAKING CLINICAL TRIALS2038Antianginal Effect of Ranolazine in Type 2 Diabetes MellitusMikhail Kosiborod, Suzanne V. Arnold, John A. Spertus, Darren K. McGuire, Yan Li, Patrick Yue,
Ori Ben-Yehuda, Amos Katz, Philip G. Jones, Ann Olmsted, Luiz Belardinelli, Bernard R. Chaitman
Diabetic patients (as compared to those without) often have extensive and diffuse coronary
artery disease and more frequent episodes of angina. This paper reports on the results of the
TERISA trial, a randomized, double-blind trial, that examines the efficacy of ranolazine
versus placebo on weekly angina frequency in subjects with type 2 diabetes, coronary artery
disease (CAD), and chronic stable angina. A total of 949 patients that were on 1 to 2 anti-
antianginals were randomized in a double-blind fashion to ranolazine or placebo. Primary
outcomes were average weekly number of angina episodes. The results reveal that weekly
angina frequency was significant lower with ranolazine versus placebo (3.8 episodes vs. 4.3
episodes, p  0.008) as was weekly sublingual nitroglycerine (1.7 doses vs. 2.1 doses
p  0.003). There were no serious adverse events. The results showed ranolazine reduced
nitroglycerine use and angina episodes in patients with diabetes, CAD, and baseline
antianginal therapy and was well tolerated.
Editorial Comment: Wilbur Y. W. Lew, Anthony N. DeMaria, p. 2046(continued on page A-18)
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ELATE-BREAKING CLINICAL TRIALS2048Results of the SELECT-ACS TrialJean-Claude Tardif, Jean-François Tanguay, Scott S. Wright, Valérie Duchatelle, Thibaut Petroni,
Jean C. Grégoire, Reda Ibrahim, Therese M. Heinonen, Stephen Robb, Olivier F. Bertrand,
Daniel Cournoyer, Dominique Johnson, Jessica Mann, Marie-Claude Guertin, Philippe L. L’Allier
The P-selectin molecule plays an active role in the inflammatory and thrombotic cascade and
is thought to contribute to the peri-procedural myocardial damage post-percutaneous coronary
intervention. This study reports on the efficacy of inclacumab, a specific monoclonal antibody
against P-selectin, in reducing myocardial damage during percutaneous coronary intervention
(PCI) in patients with non–ST-segment elevation myocardial infarction (NSTEMI). Patients
(n  544) with NSTEMI scheduled for coronary angiography and possible PCI were
andomized to pre-procedure inclacumab (2 doses) vs. placebo. Primary endpoint was a
hange in baseline troponin I (TnI). With 20 mg/kg of inclacumab, placebo-adjusted
eometric mean percent change in TnI was 24.4% at 24 h (p  0.05) and 22.4% at 16 h
p  0.07). Peak TnI was reduced by 23% (p  0.05) and area under the curve over 24 h by
3.9% (p  0.08). There was no effect of inclacumab 5 mg/kg. There were no significant
dverse events. Tardif and colleagues concluded that inclacumab appears to reduce myocardial
amage after PCI in patients with NSTEMI.ditorial Comment: Fernando Alfonso, Dominick J. Angiolillo, p. 2056INTERVENTIONAL CARDIOLOGY2060Triple Therapy With Aspirin, Prasugrel, and Vitamin K AntagonistsNikolaus Sarafoff, Amadea Martischnig Jill Wealer, Katharina Mayer, Julinda Mehilli,
Dirk Sibbing, Adnan Kastrati
Approximately 10% of patients undergoing coronary stenting have additional indication for
oral anticoagulant (OAC). The most common combination consists of aspirin, vitamin K
antagonist, and clopidogrel (triple therapy). This study evaluates whether prasugrel may serve
as an alternative to clopidogrel in patients undergoing coronary stenting and requiring triple
therapy. A total of 377 consecutive patients undergoing drug-eluting stents and also requiring
OAC were studied. Primary endpoint was composite of TIMI major and minor bleeding at
6 months. A total of 21 patients (5.6%) received prasugrel instead of clopidogrel. TIMI major
and minor bleeding occurred significantly more in prasugrel as compared to clopidogrel group
16 (28.6%) vs. 24 (6.7%) (adjusted hazard ratio: 3.2; p  0.03). There was no significant
difference regarding the combined ischemic secondary endpoints. The findings suggested that
substituting prasugrel for clopidogrel in patients needing triple therapy increased the risk of
bleeding, however, randomized trials are needed to define the role of newer adenosine
diphosphate receptor antagonist in this setting.
Editorial Comment: Paul A. Gurbel, Udaya S. Tantry, p. 2067(continued on page A-19)
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CINTERVENTIONAL CARDIOLOGY2070Sex and Bleeding Avoidance StrategiesStacie L. Daugherty, Lauren E. Thompson, Sunghee Kim, Sunil V. Rao, Sumeet Subherwal, Thomas T. Tsai,
John C. Messenger, Frederick A. Masoudi
Women have higher risk for peri-procedure bleeding following percutaneous coronary
intervention (PCI). Daugherty and colleagues evaluated the use and effectiveness of bleeding
avoidance strategies (BAS), (vascular closure device, bivalirudin, and radial access) in women
as compared to men. A total of 570,777 patients (67.5% men) were evaluated from the
National Cardiovascular Data CathPCI registry. The results revealed that the use of BAS
differed slightly between women and men (75.4% vs. 75.7%, p  0.01). Without BAS,
woman had higher rates of bleeding than men (12.5% vs. 6.2%, p  0.01). Women and men
had lower absolute bleeding risk with BAS with greater absolute risk reduction in women
(6.3% vs. 3.2%, p  0.01). The authors concluded that after PCI, women have almost twice
the rate of bleeding. BAS was associated with a similar lower risk of bleeding for both men
and women, however, the absolute risk difference was higher in women.HEART RHYTHM DISORDERS2079Renal Impairment and Stroke in Atrial FibrillationAmitava Banerjee, Laurent Fauchier, Patrick Vourc’h, Christian R. Andres, Sophie Taillandier,
Jean Michel Halimi, Gregory Y. H. Lip
Banerjee and colleagues evaluated the risk of ischemic stroke/thromboembolism (IS/TE)
associated with renal impairment and its incremented predictive value over established risk
stratification scores (CHADS2 and CHA2DS2-VASC) in patients with atrial fibrillation
AF). Patients from the Loire Valley Atrial Fibrillation Project were studied. Renal
mpairment was defined as an elevated serum creatinine level, a history of renal failure, or
ith estimated glomerular filtration rate (eGFR) at time AF diagnosis. A total of 5,912
atients with nonvalvular AF and available data on renal function were studied. Renal
mpairment by both creatinine and eGFR was associated with higher rates if IS/TE at 1 year
ompared to normal renal function. After adjustment for CHADS2 risk factors, renal
mpairment did not significantly increase the risk of IS/TE at 1 year (hazard ratio [HR]:
.06) for renal impairment and 1.09 for eGFR. Adding renal impairment to existing risk
caring system for stroke/TE (CHADS2 and CHA2 DS2VASC) did not improve predictive
alues of score. The authors concluded that renal impairment was not an independent
redictor of IS/TE in patients with AF and did not significantly improve predictive ability of
HADS2 or CHA2DS2VASC score.(continued on page A-20)
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fHEART RHYTHM DISORDERS2088Ventricular Tachycardia ChannelsStavros E. Mountantonakis, Robert E. Park, David S. Frankel, Mathew D. Hutchinson, Sanjay Dixit,
Joshua Cooper, David Callans, Francis E. Marchlinski, Edward P. Gerstenfeld
Mountantonakis and colleagues sought to evaluate the relationship of VT isthmus to channels
of preserved voltage on electroautonomic voltage map in post-infarction cardiomyopathy
patients. A total of 24 patients with post-infarction cardiomyopathy (ejection fraction:
33  9%) and tolerated VT were evaluated with detailed bipolar endocardial voltage maps.
ndocardial scar (voltage 1.5 mv), late isolated potential (LP), channels (using voltage
utoffs), and tolerated VT isthmus were identified. By adjusting voltage cutoffs, 37 channels
ere identified in 21 of 24 (87%) of patients. LP within a channel were seen in 11 of 24
atients (46%) and 17 of 36 (46%) of channels. VT isthmus site was contained within a
hannel in only 11 of 24 (46%) patients or 11 of 37 channels. Voltage channels with LPs
arbored the clinical isthmus with sensitivity and specificity of 75% and 83%, respectively.
he authors concluded that channels can be identified in 87% of patients with ischemic VT,
owever, specificity of channel in predicting location of VT isthmus site is only 30%. The
resence of LPs inside the voltage channel significantly increased the specificity of identifying
he clinical VT isthmus.ditorial Comment: Haris M. Haqqani, Joseph B. Morton, Jonathan M. Kalman, p. 2096CARDIAC IMAGING2098Coronary Calcium, Vascular Function, and PrognosisMasanao Naya, Venkatesh L. Murthy, Courtney R. Foster, Mariya Gaber, Josh Klein, Jon Hainer,
Sharmila Dorbala, Ron Blankstein, Marcelo F. Di Carli
Naya and colleagues test the hypothesis that coronary vascular dysfunction measured by
coronary flow reserve (CFR) secondary to effects of atherosclerosis on coronary epicardial and
microvascular function determined adverse prognosis irrespective of magnitude of coronary
artery calcification (CAC). A total of 901 consecutive symptomatic patients underwent
82-rubidium myocardial perfusion imaging (MPI) PET and CAC scan. The primary
endpoint was composite of major adverse cardiac events (MACE). At baseline, CFR
decreased (2.15  0.72, 2.02  0.65, and 1.88  0.64, p  0.0001) with increasing levels of
AC (0, 1 to 399, and 400). Annual risk-adjusted MACE rates were higher for patients
ith CFR 2.0 compared to 2.0 (1.9 vs. 5.5%/year, p  0.0007) but were borderline
associated with CAC (3.1, 3.4, and 6.2%/year CAC of 0, 1 to 333, and 400, p  0.09),
espectively. The authors conclude that in symptomatic patients with normal MPI, global
FR but not CAC provides significant incremental risk stratification over clinical risk score
or prediction of MACE.
